Recent Updates
Recently added Catalysts

SACT-1

Phase 1

Healthy Subject | Small molecule | Other |Aptorum Group Limited|Last Updated: May 26, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment16
FDA Designations
ORPHAN_DRUG
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05358756A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult VolunteersPHASE1 COMPLETED 16Oct 9, 2021Dec 14, 2021May 26, 20221 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Relative Bioavailability of SACT-1 and Edurant Tablet
Up to 240 hours after dosing in each study period

Compare the relative bioavailability of 150 mg SACT-1 (oral suspension) under fasted and fed conditions to 150 mg Edurant® (6 × 25 mg rilpivirine, oral tablets) under fed conditions.

Secondary Endpoints
Number of subjects with Adverse Events
Up to 14 days after the final dose of the study drug.
The effect of food (fasted or fed condition) on potential QT prolongation from administration of a single dose of 150 mg rilpivirine in healthy adult subjects.
Up to 24 hours after dosing in each study period
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Treatment A :FastedEXPERIMENTALA single adminstration of SACT-1 (150 mg rilpivirine oral suspension) after a supervised overnight fast of at least 10 hours.
Treatment B: FedEXPERIMENTALA single adminstration of SACT-1 (150 mg rilpivirine oral suspension) after a supervised overnight fast of at least 10 hours followed by a high-fat, high calorie meal (fed).Subjects started the standardized high-fat, high-calorie breakfast 30 minutes prior to dosing and consumed this meal within the 30 minutes before dosing.
Treatment C: FedACTIVE_COMPARATORAdminstartion of Edurant, 150 mg (6 × 25 mg rilpivirine, oral tablets), after a supervised overnight fast of at least 10 hours followed by a high-fat, high calorie meal (fed).Subjects started the standardized high-fat, high-calorie breakfast 30 minutes prior to dosing and consumed this meal within the 30 minutes before dosing.
Interventions
NameTypeDescription
SACT-1DRUGSingle administartion of 150mg SACT-1
EDURANT 25Mg TabletDRUGSingle administartion of six EDURANT 25mg tablets (Total 150mg)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Healthy male or female volunteers ≥ 18 years of age. 2. Males or non-pregnant, non-lactating females who are postmenopausal, naturally or surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior to study initiation or hysterectomy), or who agree to use...

Countries:United States
Unlock Eligibility Criteria